NEW YORK (GenomeWeb News) – ExonHit Therapeutics today said that it has licensed from Institut Gustave Roussy exclusive, worldwide rights to a tissue-based breast cancer signature that will developed into an assay.

Paris-based ExonHit plans to validate IGR's signature in a larger population and will have access to samples from IGR's biobank. The firm intends to launch a research-use-only test within 12 months. Following further validation, it intends to launch a clinical diagnostic assay based on the signature.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.

The new Francis Crick Institute building can get too noisy for some researchers to concentrate, according to the Guardian.

CBS News reports that there are still many vacancies at the White House Office of Science and Technology Policy, but that it's uncertain whether they will be filled.

In Nucleic Acids Research this week: pipeline to analyze and visualize bacterial genomes, database of global set of human genomes, and more.